SI3142701T1 - Novo zdravljenje - Google Patents
Novo zdravljenje Download PDFInfo
- Publication number
- SI3142701T1 SI3142701T1 SI201530328T SI201530328T SI3142701T1 SI 3142701 T1 SI3142701 T1 SI 3142701T1 SI 201530328 T SI201530328 T SI 201530328T SI 201530328 T SI201530328 T SI 201530328T SI 3142701 T1 SI3142701 T1 SI 3142701T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- cftr
- use according
- patient
- mutation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims abstract 12
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims abstract 12
- 239000002253 acid Substances 0.000 claims abstract 5
- CSOBIBXVIYAXFM-UHFFFAOYSA-N rpl-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 230000035772 mutation Effects 0.000 claims 7
- 108700028369 Alleles Proteins 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 102200128591 rs78655421 Human genes 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000008275 microscopic colitis Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 102200132105 rs193922525 Human genes 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 abstract 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 208000024632 Idiopathic bronchiectasis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000007466 Male Infertility Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 210000001177 vas deferen Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
- NOVO ZDRAVLJENJE PATENTNI ZAHTEVKI1. Spojina za uporabo pri zdravljenju ali preprečevanju cistične fibroze pri pacientu z modulacijo aktivnosti CFTR, ta spojina pa je 9,10-dimetoksi-2-(2,4,6-trimetilfenilimino)-3-(N-karbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]izokinolin-4-on ali njena farmacevtsko sprejemljiva kislinska adicijska sol.
- 2. Spojina za uporabo v skladu z zahtevkom 1, značilna po tem, da ima pacient mutacijo CFTR.
- 3. Spojina za uporabo v skladu z zahtevkom 2, značilna po tem, da je mutacija CFTR mutacija CFTR razreda III ali mutacija CFTR razreda IV.
- 4. Spojina za uporabo v skladu z zahtevkom 2, značilna po tem, da je mutacija CFTR G551D, G178R, G551S, S549N, G1349D, R117H, R117C, R347P ali R334W.
- 5. Spojina za uporabo v skladu s katerim koli od zahtevkov 2 do 4, značilna po tem, da je mutacija CFTR R117H.
- 6. Spojina za uporabo v skladu s katerim koli od predhodnih zahtevkov, značilna po tem, da je pacient heterozigot z (i) enim alelom, ki kaže mutacijo CFTR razreda III ali razreda IV, in (ii) drugim alelom, ki kaže mutacijo CFTR razreda II.
- 7. Spojina za uporabo v skladu s katerim koli od predhodnih zahtevkov, značilna po tem, da je pacient dovzeten za ali ima diarejo.
- 8. Spojina za uporabo v skladu s katerim koli od predhodnih zahtevkov, značilna po tem, da ima pacient ulcerozni kolitis, Crohnovo bolezen, mikroskopski kolitis, celiakijo, sindrom razdražljivega črevesja, malabsorbcijo žolčne kisline ali divertikulitis.
- 9. Spojina za uporabo v skladu s katerim koli od predhodnih zahtevkov, značilna po tem, da je spojina za dajanje z inhalacijo.
- 10. Spojina za uporabo pri povečanju mobilnosti sluzi in/ali zmanjšanju viskoznosti sluzi ali za uporabo pri olajšanju čiščenja sluznice dihal pri pacientu s cistično fibrozo, ta spojina pa je 9,10-dimetoksi-2-(2,4,6-trimetilfenilimino)-3-(N-karbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]izokinolin-4-on ali njena farmacevtsko sprejemljiva kislinska adicijska sol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1408384.4A GB201408384D0 (en) | 2014-05-12 | 2014-05-12 | New treatment |
| GBGB1417719.0A GB201417719D0 (en) | 2014-10-07 | 2014-10-07 | New treatment |
| PCT/GB2015/051377 WO2015173551A1 (en) | 2014-05-12 | 2015-05-11 | New treatment |
| EP15724354.4A EP3142701B1 (en) | 2014-05-12 | 2015-05-11 | New treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3142701T1 true SI3142701T1 (sl) | 2018-08-31 |
Family
ID=53264683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530328T SI3142701T1 (sl) | 2014-05-12 | 2015-05-11 | Novo zdravljenje |
| SI201531105T SI3231444T1 (sl) | 2014-05-12 | 2015-05-11 | Novo zdravljenje |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531105T SI3231444T1 (sl) | 2014-05-12 | 2015-05-11 | Novo zdravljenje |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10864213B2 (sl) |
| EP (2) | EP3231444B1 (sl) |
| AU (1) | AU2015261239B2 (sl) |
| CA (1) | CA2948620C (sl) |
| CY (2) | CY1120550T1 (sl) |
| DK (2) | DK3231444T3 (sl) |
| ES (2) | ES2682105T3 (sl) |
| HU (1) | HUE048020T2 (sl) |
| IL (1) | IL248856B (sl) |
| MX (1) | MX2016014756A (sl) |
| PL (2) | PL3142701T3 (sl) |
| PT (2) | PT3231444T (sl) |
| RU (1) | RU2688191C2 (sl) |
| SI (2) | SI3142701T1 (sl) |
| WO (1) | WO2015173551A1 (sl) |
| ZA (1) | ZA201607705B (sl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| EP3045452A1 (en) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Process of producing cycloalkylcarboxamido-indole compounds |
| HUE062736T2 (hu) | 2014-04-15 | 2023-12-28 | Vertex Pharma | Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére |
| AU2015261239B2 (en) | 2014-05-12 | 2020-02-27 | Verona Pharma Plc | New treatment |
| SI3193835T1 (sl) | 2014-09-15 | 2018-06-29 | Verona Pharma PLC Bradley Court | Tekoči pripravek za inhaliranje, ki vsebuje rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| CA3160752A1 (en) * | 2019-12-26 | 2021-07-01 | Preston E. BRATCHER | Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455946B (sv) | 1986-10-20 | 1988-08-22 | Trion Forskning & Utveckling | Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| AU2178392A (en) | 1991-06-12 | 1993-01-12 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| ATE150296T1 (de) | 1991-12-18 | 1997-04-15 | Minnesota Mining & Mfg | Aerosolzusammensetzungen für arzneimittelsuspensionen |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| PL343491A1 (en) | 1998-04-18 | 2001-08-27 | Glaxo Group Ltd | Pharmaceutical aerosol formulation |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| ES2208310T3 (es) * | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| JP2002541183A (ja) | 1999-04-14 | 2002-12-03 | グラクソ グループ リミテッド | 医薬用エアゾール製剤 |
| CN101891680B (zh) | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| ES2532753T3 (es) | 2008-11-06 | 2015-03-31 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| MX2012002967A (es) | 2009-09-11 | 2012-04-30 | Chiesi Farma Spa | Derivados de isoxazolidina. |
| PT2603509E (pt) * | 2010-08-09 | 2014-08-29 | Verona Pharma Plc | Forma cristalina de um composto pirimidio[6,1-a]isoquinolin-4-ona |
| WO2012069275A1 (en) | 2010-11-26 | 2012-05-31 | Chiesi Farmaceutici S.P.A. | Glycine derivatives and their use as muscarinic receptor antagonists |
| WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
| WO2013024164A1 (en) * | 2011-08-18 | 2013-02-21 | Shire Ag | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| NZ629199A (en) | 2012-02-27 | 2017-01-27 | Vertex Pharma | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| WO2014140747A2 (en) | 2013-03-14 | 2014-09-18 | Lincoln Global, Inc. | Systems and methods of exporting or using welding sequencer data for external systems |
| LT2968313T (lt) | 2013-03-15 | 2018-05-10 | Verona Pharma Plc | Vaistų derinys |
| AU2015261239B2 (en) | 2014-05-12 | 2020-02-27 | Verona Pharma Plc | New treatment |
| SI3193835T1 (sl) | 2014-09-15 | 2018-06-29 | Verona Pharma PLC Bradley Court | Tekoči pripravek za inhaliranje, ki vsebuje rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
-
2015
- 2015-05-11 AU AU2015261239A patent/AU2015261239B2/en active Active
- 2015-05-11 EP EP17174446.9A patent/EP3231444B1/en active Active
- 2015-05-11 CA CA2948620A patent/CA2948620C/en active Active
- 2015-05-11 ES ES15724354.4T patent/ES2682105T3/es active Active
- 2015-05-11 ES ES17174446T patent/ES2773142T3/es active Active
- 2015-05-11 WO PCT/GB2015/051377 patent/WO2015173551A1/en active Application Filing
- 2015-05-11 US US15/310,693 patent/US10864213B2/en active Active
- 2015-05-11 PT PT171744469T patent/PT3231444T/pt unknown
- 2015-05-11 EP EP15724354.4A patent/EP3142701B1/en active Active
- 2015-05-11 PL PL15724354T patent/PL3142701T3/pl unknown
- 2015-05-11 MX MX2016014756A patent/MX2016014756A/es active IP Right Grant
- 2015-05-11 PL PL17174446T patent/PL3231444T3/pl unknown
- 2015-05-11 DK DK17174446.9T patent/DK3231444T3/da active
- 2015-05-11 RU RU2016148447A patent/RU2688191C2/ru active
- 2015-05-11 SI SI201530328T patent/SI3142701T1/sl unknown
- 2015-05-11 HU HUE17174446A patent/HUE048020T2/hu unknown
- 2015-05-11 DK DK15724354.4T patent/DK3142701T3/en active
- 2015-05-11 PT PT15724354T patent/PT3142701T/pt unknown
- 2015-05-11 SI SI201531105T patent/SI3231444T1/sl unknown
-
2016
- 2016-11-08 ZA ZA2016/07705A patent/ZA201607705B/en unknown
- 2016-11-09 IL IL248856A patent/IL248856B/en active IP Right Grant
-
2018
- 2018-08-09 CY CY20181100831T patent/CY1120550T1/el unknown
-
2020
- 2020-02-19 CY CY20201100153T patent/CY1122748T1/el unknown
- 2020-11-16 US US17/099,598 patent/US11759467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016148447A3 (sl) | 2018-12-27 |
| US10864213B2 (en) | 2020-12-15 |
| EP3142701B1 (en) | 2018-06-27 |
| CA2948620C (en) | 2023-01-24 |
| DK3142701T3 (en) | 2018-08-13 |
| MX2016014756A (es) | 2017-03-23 |
| RU2688191C2 (ru) | 2019-05-21 |
| CY1122748T1 (el) | 2021-03-12 |
| PL3231444T3 (pl) | 2020-05-18 |
| RU2016148447A (ru) | 2018-06-19 |
| US11759467B2 (en) | 2023-09-19 |
| IL248856B (en) | 2020-07-30 |
| PT3231444T (pt) | 2020-03-05 |
| ES2682105T3 (es) | 2018-09-18 |
| HUE048020T2 (hu) | 2020-05-28 |
| ES2773142T3 (es) | 2020-07-09 |
| US20210106585A1 (en) | 2021-04-15 |
| US20170112839A1 (en) | 2017-04-27 |
| SI3231444T1 (sl) | 2020-04-30 |
| EP3231444B1 (en) | 2019-12-18 |
| AU2015261239B2 (en) | 2020-02-27 |
| ZA201607705B (en) | 2020-05-27 |
| CA2948620A1 (en) | 2015-11-19 |
| PL3142701T3 (pl) | 2018-11-30 |
| EP3142701A1 (en) | 2017-03-22 |
| IL248856A0 (en) | 2017-01-31 |
| AU2015261239A1 (en) | 2016-12-01 |
| DK3231444T3 (da) | 2020-03-16 |
| WO2015173551A1 (en) | 2015-11-19 |
| EP3231444A1 (en) | 2017-10-18 |
| CY1120550T1 (el) | 2019-07-10 |
| PT3142701T (pt) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3142701T1 (sl) | Novo zdravljenje | |
| CY1122500T1 (el) | Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων | |
| BR112014016233A8 (pt) | inibidores de bromodomínio | |
| MX2017012558A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso. | |
| WO2015101958A3 (en) | Inhibitors of glutaminase | |
| MX2019005533A (es) | Tratamiento de la fibrosis. | |
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| MY183969A (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| RS53995B1 (en) | NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE | |
| JP2016540749A5 (sl) | ||
| JP2016531861A5 (sl) | ||
| MX2017006049A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidro piridinas como inhibidores de bace1. | |
| EA033530B1 (ru) | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида | |
| WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
| NZ724057A (en) | Treatment of intrahepatic cholestatic diseases | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| UA109867C2 (ru) | Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar) | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| PH12016501548B1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
| MX2023011546A (es) | Composiciones nasales que comprenden alcaftadina. | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| NZ736551A (en) | Indole derivatives |